Misplaced Pages

Atilotrelvir

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

Pharmaceutical compound
Atilotrelvir
Clinical data
Other namesGST-HG171
Identifiers
IUPAC name
  • (1S,3S,4R)-N-ethyl]-2-butanoyl]spiroheptane-5,1'-cyclopropane]-3-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
FormulaC24H32F3N5O4
Molar mass511.546 g·mol
3D model (JSmol)
SMILES
  • CC(C)(C)(C(=O)N12C(1C(=O)N(C3CCNC3=O)C#N)C4(C2)CC4)NC(=O)C(F)(F)F
InChI
  • InChI=InChI=1S/C24H32F3N5O4/c1-22(2,3)17(31-21(36)24(25,26)27)20(35)32-14-9-15(23(10-14)5-6-23)16(32)19(34)30-13(11-28)8-12-4-7-29-18(12)33/h12-17H,4-10H2,1-3H3,(H,29,33)(H,30,34)(H,31,36)/t12-,13-,14-,15-,16-,17+/m0/s1
  • Key:GTRJFXDJASEGSW-KBCNZALWSA-N

Atilotrelvir (development code GST-HG171) is a drug for the treatment of COVID-19. It has broad-spectrum anti-SARS-CoV-2 activity against different variants (including WT, β, δ, and omicron).

In combination with ritonavir, it was approved for use in China in 2023.

References

  1. Lu H, Zhang G, Mao J, Chen X, Zhan Y, Lin L, et al. (May 2024). "Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial". eClinicalMedicine. 71: 102582. doi:10.1016/j.eclinm.2024.102582. PMC 11015484. PMID 38618202.
  2. Zhang G, Mao J, He H, Xu K, Zhou J, Yang Y, et al. (2023). "Discovery of GST-HG171, A Potent and Selective Oral 3CL Protease Inhibitor for the Treatment of COVID-19" (PDF). SM Journal of Infectious Diseases. 6 (9).
  3. Zhang H, Zhou J, Chen H, Mao J, Tang Y, Yan W, et al. (January 2024). "Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171". Antimicrobial Agents and Chemotherapy. 68 (1): e0111523. doi:10.1128/aac.01115-23. PMC 10777829. PMID 38099673.
  4. Zheng L, Wang W, Sun Q (February 2024). "Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA". Signal Transduction and Targeted Therapy. 9 (1): 46. doi:10.1038/s41392-024-01770-y. PMC 10879080. PMID 38378623.
RNA virus antivirals (primarily J05, also S01AD and D06BB)
Hepatitis C
NS3/4A protease inhibitors (–previr)
NS5A inhibitors (–asvir)
NS5B RNA polymerase inhibitors (–buvir)
Combination drugs
Hepatitis D
Picornavirus
Anti-influenza agents
Multiple/general
Interferon
3CL protease inhibitors (–trelvir)
RNA pol inhibitors
Multiple/Unknown/Other
Stub icon

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: